Receptor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 125: Line 125:
hGPR40 has a distinct binding pocket that is established by <scene name='72/721541/All_binding_residues/3'>8 key residues</scene>: <scene name='72/721541/Tyr91/1'>Tyr91</scene>, <scene name='72/721541/Glu172/2'>Glu172</scene>, <scene name='72/721541/Arg183/2'>Arg183</scene>, <scene name='72/721541/Ser187/2'>Ser187</scene>, <scene name='72/721541/Tyr240/1'>Tyr240</scene>, <scene name='72/721541/Asn241/1'>Asn241</scene>, <scene name='72/721541/Asn244/1'>Asn244</scene>, and <scene name='72/721541/Arg258/1'>Arg258</scene> (all individual residues shown in chartreuse). The importance of these residues for agonist binding was determined by alanine site-directed-mutagenesis mutagenesis studies. When the substrate (an agonist) enters the binding pocket, 4 of the 8 <scene name='72/721541/Hydrogen_binding_1/8'>key binding residues</scene> interact directly with the carboxylate moiety of the agonist by hydrogen bonding to it. These residues include 2 key arginines in the binding pocket, Arg183 and Arg258,<ref name="Sum">PMID: 17699519</ref><ref name="Sum, C.">PMID:19068482</ref> and 2 key tyrosine residues, Tyr91 and Tyr240. Tyr240 is especially important for binding, as mutation of Tyr240 caused an eight fold reduction in the binding affinity of TAK-875 and had a significant effect on the binding affinity (K<sub>D</sub>) of the protein.
hGPR40 has a distinct binding pocket that is established by <scene name='72/721541/All_binding_residues/3'>8 key residues</scene>: <scene name='72/721541/Tyr91/1'>Tyr91</scene>, <scene name='72/721541/Glu172/2'>Glu172</scene>, <scene name='72/721541/Arg183/2'>Arg183</scene>, <scene name='72/721541/Ser187/2'>Ser187</scene>, <scene name='72/721541/Tyr240/1'>Tyr240</scene>, <scene name='72/721541/Asn241/1'>Asn241</scene>, <scene name='72/721541/Asn244/1'>Asn244</scene>, and <scene name='72/721541/Arg258/1'>Arg258</scene> (all individual residues shown in chartreuse). The importance of these residues for agonist binding was determined by alanine site-directed-mutagenesis mutagenesis studies. When the substrate (an agonist) enters the binding pocket, 4 of the 8 <scene name='72/721541/Hydrogen_binding_1/8'>key binding residues</scene> interact directly with the carboxylate moiety of the agonist by hydrogen bonding to it. These residues include 2 key arginines in the binding pocket, Arg183 and Arg258,<ref name="Sum">PMID: 17699519</ref><ref name="Sum, C.">PMID:19068482</ref> and 2 key tyrosine residues, Tyr91 and Tyr240. Tyr240 is especially important for binding, as mutation of Tyr240 caused an eight fold reduction in the binding affinity of TAK-875 and had a significant effect on the binding affinity (K<sub>D</sub>) of the protein.
-
hGPR40 contains a highly conserved hairpin extracellular loop. This extracellular loop (<scene name='72/721541/Ecl2/4'>ECL2</scene>) is the longest and most divergent of the extracellular loops found in proteins (<scene name='72/721541/Ecl2_top/2'>top view of ECL2</scene>). The loop is accompanied by a [https://en.wikibooks.org/wiki/Structural_Biochemistry/Chemical_Bonding/_Disulfide_bonds disulfide bond] (<scene name='72/721541/Cysteine_bridge/3'>Cys79 and Cys170</scene>) that forms between transmembrane helix 4 and the C-terminus of the ECL2 loop. In hGPR40, ECL2 has two sections: a <FONT COLOR="#00FFFF">'''beta sheet'''</FONT> and an <FONT COLOR="#FF00FF">'''auxiliary loop'''</FONT>. The [https://en.wikipedia.org/wiki/Beta_sheet beta sheet] spans helices 4 and 5 and is shorter in hGPR40 than in other GPCRs. The ECL2 of hGPR40 also differs from that of other proteins because it contains an auxiliary loop of 13 extra residues. The entire extracellular loop has low mobility and flexibility, which allows it to act as a cap for the binding pocket. The only exception to the low flexibility is the tip of the auxiliary loop, which corresponds to residues Asp152-Asn155. This area of greater mobility allows for substrates to enter the binding site.<ref name="Srivastava"/>
+
hGPR40 contains a highly conserved hairpin extracellular loop (<scene name='72/721541/Ecl2/4'>ECL2</scene>) is the longest and most divergent of the extracellular loops found in proteins (<scene name='72/721541/Ecl2_top/2'>top view of ECL2</scene>). The loop is accompanied by a disulfide bond (<scene name='72/721541/Cysteine_bridge/3'>Cys79 and Cys170</scene>) that forms between transmembrane helix 4 and the C-terminus of the ECL2 loop. In hGPR40, ECL2 has two sections: a <FONT COLOR="#00FFFF">'''beta sheet'''</FONT> and an <FONT COLOR="#FF00FF">'''auxiliary loop'''</FONT>. The beta sheet spans helices 4 and 5 and is shorter in hGPR40 than in other GPCRs. The ECL2 of hGPR40 also differs from that of other proteins because it contains an auxiliary loop of 13 extra residues. The entire extracellular loop has low mobility and flexibility, which allows it to act as a cap for the binding pocket. The only exception to the low flexibility is the tip of the auxiliary loop, which corresponds to residues Asp152-Asn155. This area of greater mobility allows for substrates to enter the binding site.
-
<scene name='72/727085/Hgpr40_begin/3'>Tak-875</scene> is a [https://en.wikipedia.org/wiki/Partial_agonist partial agonist] of GPR40 and tested for the treatment of type 2 diabetes. The binding of TAK-875 to hGPR40 occurs by the ligand entering the binding site through the [https://en.wikipedia.org/wiki/Cell_membrane membrane bilayer]. This membrane insertion is performed via a method similar to ligand binding to [https://en.wikipedia.org/wiki/Sphingosine-1-phosphate_receptor sphingosine 1-phosphate receptor 1], retinal loading of [http://proteopedia.org/wiki/index.php/4j4q GPCR opsin], and the entry of anandamide in [https://en.wikipedia.org/wiki/Cannabinoid_receptor cannabinoid receptors], in which the <scene name='72/727085/Ecl2/4'>extracellular loops</scene> block the binding from the extracellular matrix <ref>PMID:22344443</ref>.
+
<scene name='72/727085/Hgpr40_begin/3'>Tak-875</scene> is a partial agonist of GPR40 and tested for the treatment of type 2 diabetes. The binding of TAK-875 to hGPR40 occurs by the ligand entering the binding site through the membrane bilayer. This membrane insertion is performed via a method similar to ligand binding to sphingosine 1-phosphate receptor 1, retinal loading of GPCR opsin, and the entry of anandamide in cannabinoid receptors, in which the <scene name='72/727085/Ecl2/4'>extracellular loops</scene> block the binding from the extracellular matrix <ref>PMID:22344443</ref>.
TAK-875 binds to the <scene name='72/727085/Hgpr40_entry/2'>noncanonical binding site </scene> created between transmembrane (TM) domains 3-5 and the extracellular loop 2 (ECL2) of hGPR40. The ECL2 and auxiliary loop form a roof causing TAK-875 to enter through TM3 and TM4, first passing through the lipid bilayer. The carboxylate of TAK-875 is buried within a very hydrophobic region and in a complex complex <scene name='72/727085/Hgpr40_binding_relay/6'>charge network</scene> involving Glu172, Ser187, Asn241, and Asn 244 from hGPR40 forming ionic and polar interactions by coordinating TAK-875 with Arg183, Arg258, Tyr91, and Tyr240.
TAK-875 binds to the <scene name='72/727085/Hgpr40_entry/2'>noncanonical binding site </scene> created between transmembrane (TM) domains 3-5 and the extracellular loop 2 (ECL2) of hGPR40. The ECL2 and auxiliary loop form a roof causing TAK-875 to enter through TM3 and TM4, first passing through the lipid bilayer. The carboxylate of TAK-875 is buried within a very hydrophobic region and in a complex complex <scene name='72/727085/Hgpr40_binding_relay/6'>charge network</scene> involving Glu172, Ser187, Asn241, and Asn 244 from hGPR40 forming ionic and polar interactions by coordinating TAK-875 with Arg183, Arg258, Tyr91, and Tyr240.
 +
*[[Lysophosphatidic acid receptor]]
*[[Lysophosphatidic acid receptor]]
*[[User:Harish Srinivas/Sandbox 1|Sphingosine 1-phosphate Receptor]]
*[[User:Harish Srinivas/Sandbox 1|Sphingosine 1-phosphate Receptor]]

Revision as of 14:51, 21 April 2021

Nicotinic Acetylcholine Receptor, PDB code 2bg9

Drag the structure with the mouse to rotate

References

  1. De Rienzo F, Moura Barbosa AJ, Perez MA, Fernandes PA, Ramos MJ, Menziani MC. The extracellular subunit interface of the 5-HT(3) receptors: a computational alanine scanning mutagenesis study. J Biomol Struct Dyn. 2012 Jul;30(3):280-98. Epub 2012 Jun 12. PMID:22694192 doi:10.1080/07391102.2012.680029
  2. Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, Kobilka BK. Structure of the delta-opioid receptor bound to naltrindole. Nature. 2012 May 16;485(7398):400-4. doi: 10.1038/nature11111. PMID:22596164 doi:10.1038/nature11111
  3. Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, Kobilka BK. Structure of the delta-opioid receptor bound to naltrindole. Nature. 2012 May 16;485(7398):400-4. doi: 10.1038/nature11111. PMID:22596164 doi:10.1038/nature11111
  4. Krumm BE, White JF, Shah P, Grisshammer R. Structural prerequisites for G-protein activation by the neurotensin receptor. Nat Commun. 2015 Jul 24;6:7895. doi: 10.1038/ncomms8895. PMID:26205105 doi:http://dx.doi.org/10.1038/ncomms8895
  5. Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX orexin receptor bound to the insomnia drug suvorexant. Nature. 2014 Dec 22. doi: 10.1038/nature14035. PMID:25533960 doi:http://dx.doi.org/10.1038/nature14035
  6. Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, Costanzi S, Gershengorn MC. Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem. 2007 Oct 5;282(40):29248-55. Epub 2007 Aug 15. PMID:17699519 doi:http://dx.doi.org/10.1074/jbc.M705077200
  7. Sum CS, Tikhonova IG, Costanzi S, Gershengorn MC. Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem. 2009 Feb 6;284(6):3529-36. doi: 10.1074/jbc.M806987200. Epub 2008, Dec 8. PMID:19068482 doi:http://dx.doi.org/10.1074/jbc.M806987200
  8. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, Desale H, Clemons B, Cahalan SM, Schuerer SC, Sanna MG, Han GW, Kuhn P, Rosen H, Stevens RC. Crystal structure of a lipid G protein-coupled receptor. Science. 2012 Feb 17;335(6070):851-5. PMID:22344443 doi:10.1126/science.1215904
  9. Segaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol. 2015 Jan 23;4(1):1-12. doi: 10.1016/j.jbo.2015.01.001. eCollection , 2015 Mar. PMID:26579483 doi:http://dx.doi.org/10.1016/j.jbo.2015.01.001
  10. Li MJ, Greenblatt HM, Dym O, Albeck S, Pais A, Gunanathan C, Milstein D, Degani H, Sussman JL. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators. J Med Chem. 2011 Apr 7. PMID:21473635 doi:10.1021/jm200192y

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Personal tools